On crushing of deutetrabenazine tablets.
作者信息
Knebel Helena, Alexander Jessica, Wilhelm Amanda, Loupe Pippa, Schneider Frank, Gordon Mark Forrest
机构信息
Medical Scientific Unit Global Research and Development Teva Pharmaceutical Industries, Ltd Netanya, Israel.
Global Research and Development Teva Pharmaceutical Industries, Ltd West Chester, PA.
出版信息
Am J Health Syst Pharm. 2021 Aug 30;78(17):1551-1552. doi: 10.1093/ajhp/zxab130.
Abstract
摘要
相似文献
1
On crushing of deutetrabenazine tablets.关于去甲丁苯那嗪片的碾碎情况。
Am J Health Syst Pharm. 2021 Aug 30;78(17):1551-1552. doi: 10.1093/ajhp/zxab130.
2
Crushing of deutetrabenazine tablets limited to individual case.
Am J Health Syst Pharm. 2021 Aug 30;78(17):1552-1553. doi: 10.1093/ajhp/zxab128.
3
Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.粉碎盐酸丁苯那嗪治疗严重口面症状的迟发性运动障碍 1 例报告。
Am J Health Syst Pharm. 2020 Sep 4;77(18):1477-1481. doi: 10.1093/ajhp/zxaa205.
4
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.氘代丁苯那嗪（阿速得）用于治疗亨廷顿舞蹈病和迟发性运动障碍。
Med Lett Drugs Ther. 2018 Apr 23;60(1545):65-68.
5
Deutetrabenazine in the treatment of tardive dyskinesia.丁苯那嗪治疗迟发性运动障碍
Neurodegener Dis Manag. 2019 Apr;9(2):59-71. doi: 10.2217/nmt-2018-0042. Epub 2019 Jan 31.
6
Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.曲美他嗪治疗迟发性运动障碍和亨廷顿舞蹈病相关的舞蹈症：临床试验数据综述。
Expert Opin Pharmacother. 2019 Dec;20(18):2209-2221. doi: 10.1080/14656566.2019.1674281. Epub 2019 Oct 15.
7
Deuterium Tetrabenazine for Tardive Dyskinesia.用于迟发性运动障碍的氘代丁苯那嗪
Clin Schizophr Relat Psychoses. 2018 Jan;11(4):214-220. doi: 10.3371/CSRP.CUPR.010318.
8
Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.氘代丁苯那嗪：用于治疗亨廷顿舞蹈病、迟发性运动障碍和抽动秽语综合征的运动亢进症状。
Drugs Today (Barc). 2017 Feb;53(2):89-102. doi: 10.1358/dot.2017.53.2.2589164.
9
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.用于迟发性运动障碍的VMAT2抑制剂——实践意义
J Pharm Pract. 2019 Aug;32(4):450-457. doi: 10.1177/0897190018756512. Epub 2018 Feb 18.
10
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.氘代丁苯那嗪治疗迟发性运动障碍患者不自主运动的研究（AIM-TD）：一项双盲、随机、安慰剂对照的3期试验。
Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.
引用本文的文献
1
Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors.囊泡单胺转运体2抑制剂的临床经验与治疗考量
Ment Health Clin. 2024 Dec 2;14(6):304-312. doi: 10.9740/mhc.2024.12.304. eCollection 2024 Dec.
Zotero 插件